v3.25.4
Business Segment Information
 3 Months Ended
Jan. 31, 2026
Segment Reporting [Abstract]  
Business Segment Information
Note 10. Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that our Chief Operating Decision Maker (CODM) organizes segments within the Company for making operating decisions and assessing financial performance. Our CODM is our Chief Executive Officer. The Company's two operating segments are described below.
•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.
•CooperSurgical. Competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.
The CODM uses operating income, as presented in our financial reports, as the primary measure of segment profitability to assess the performance of the segments and make decisions on resource allocation across segments. The CODM evaluates segment operating income on a quarterly basis by comparing actual results to forecasted amounts and historical performance. These evaluations, supported by discussions with the leadership team responsible for managing the operations of each reportable segment, are used to assess segment results, monitor operating trends, and support decisions regarding the allocation of resources and consideration of investment opportunities. The Company does not allocate costs from corporate functions to segment operating income. The Company uses the same accounting policies to generate segment results as it does for consolidated results.
The following tables present revenue and other financial information by reportable segment:
Segment information:
Periods Ended January 31,Three Months
(In millions)20262025
CooperVision net sales by category:
Toric and multifocal$351.2 $319.4 
Sphere, other343.9 326.7 
Total CooperVision net sales$695.1 $646.1 
CooperSurgical net sales by category:
Office and surgical$202.4 $198.9 
Fertility126.6 119.7 
Total CooperSurgical net sales329.0 318.6 
Total net sales$1,024.1 $964.7 
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
Three Months Ended January 31, 2026
Net sales$695.1 $329.0 $— $1,024.1 
Cost of sales220.8 108.1 — 328.9 
Selling, general and administrative expense237.6 128.4 24.2 390.2 
Research and development expense22.4 21.9 — 44.3 
Amortization expense4.1 43.8 — 47.9 
Operating income (loss)$210.2 $26.8 $(24.2)$212.8 
Interest expense22.4 
Other expense (income), net
(1.8)
Income before income taxes$192.2 
Depreciation expense$41.1 $6.5 $— $47.6 
Capital expenditures$94.2 $8.0 $— $102.2 
As of January 31, 2026
Identifiable assets$7,655.7 $4,584.6 $183.9 $12,424.2 
Three Months Ended January 31, 2025
Net sales$646.1 $318.6 $— $964.7 
Cost of sales205.0 99.5 — 304.5 
Selling, general and administrative expense229.9 135.9 22.1 387.9 
Research and development expense22.5 18.2 — 40.7 
Amortization expense4.8 44.8 — 49.6 
Operating income (loss)$183.9 $20.2 $(22.1)$182.0 
Interest expense26.0 
Other expense (income), net
2.7 
Income before income taxes$153.3 
Depreciation expense$35.3 $6.1 $— $41.4 
Capital expenditures$75.6 $13.8 $— $89.4 
As of October 31, 2025
Identifiable assets$7,604.4 $4,619.3 $171.1 $12,394.8 
(1) Corporate SGA expenses are not allocated to the segments.
Geographic information:
Periods Ended January 31,Three Months
(In millions)20262025
Net sales to unaffiliated customers by country of domicile:
United States$513.9 $496.4 
Europe326.4 287.5 
Rest of world183.8 180.8 
Total$1,024.1 $964.7 
(In millions)January 31, 2026October 31, 2025
Net property, plant and equipment by country of domicile:
United States$1,406.0 $1,389.4 
Europe449.0 429.1 
Rest of world261.7 263.5 
Total$2,116.7 $2,082.0